Induction chemotherapy

Phase 2

CChang Gung Memorial Hospital

Induction chemotherapy is one of 64 therapeutic programs targeting High-Risk Neuroblastoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

High-Risk NeuroblastomaNot yet recruiting

Esophageal CancerRecruiting

High-Risk NeuroblastomaPhase 1

Not yet recruiting

Esophageal CancerPhase 2

Recruiting

Competition

Competitive Landscape

99 competitors in Esophageal Cancer

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 3

48 2

Eloxatin

Teva

Phase 3

32 3

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

58 4

Opdivo

Bristol-Myers Squibb

Phase 3

13 5

Paraplatin

AAvyxa

Phase 3

31 6

Keytruda

Merck & Co.

Phase 3

11 7

Taxotere

AAvyxa

Phase 3

21 8

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

19 9

Herceptin

Perjeta

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2032

Phase 2Recruiting

Esophageal Cancer

NCT06906887

Q4 2032

Phase 1Not yet recruiting

High-Risk Neuroblastoma

NCT07688252

Clinical

Trials by Indication[1]

Esophageal Cancer1 trial

PULSO Trial: Pulsed Low-Dose-Rate (PLDR) Radiation Chemoradiation (CRT) vs. Standard CRT for Esophageal Cancer

Recruiting·MMedical College of Wisconsin·Phase 2·NCT06906887·50 enrolled

High-Risk Neuroblastoma1 trial

Pilot Study of Combining of Dinutuximab-β With Induction Chemotherapy in Newly Diagnosed High Risk Neuroblastoma

Not yet recruiting·CChang Gung Memorial Hospital·Phase 1·NCT07688252·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Induction chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Induction chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Chang Gung Memorial Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: CChang Gung Memorial Hospital

Induction chemotherapy

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2032

Q4 2032

Trials by Indication[1]

Esophageal Cancer1 trial

High-Risk Neuroblastoma1 trial

References

Drug Info

Quick Facts

Related News